EGFR and metastatic neoplasm: STAT3 represents a particular promising target in this tumor entity, because, especially for patients with recurrent or metastatic disease, RT can be combined with an EGFR inhibitor, as activation of EGFR signaling commonly stimulates STAT3 phosphorylation [84,85].